MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek; Chih-Cheng Chen; Miklós Egyed; Martin Ellis; Laura Fox; Yeow T Goh; Vikas Gupta; Claire Harrison; Jean-Jacques Kiladjian; Mihaela C Lazaroiu; Adam Mead; Donal McLornan; Mary F McMullin; Stephen T Oh; Andrew Perkins; Uwe Platzbecker; Christof Scheid; Alessandro Vannucchi; Sung-Soo Yoon; Mark M Kowalski; Ruben A Mesa

doi:10.2217/fon-2020-1048

MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, Martin Ellis, Laura Fox, Yeow T Goh, Vikas Gupta, Claire Harrison, Jean-Jacques Kiladjian, Mihaela C Lazaroiu, Adam Mead, Donal McLornan, Mary F McMullin, Stephen T Oh, Andrew Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Vannucchi, Sung-Soo Yoon, Mark M KowalskiRuben A Mesa

Queen's University Belfast

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

287 Downloads (Pure)

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Original language	English
Journal	Future oncology (London, England)
Early online date	11 Jan 2021
DOIs	https://doi.org/10.2217/fon-2020-1048
Publication status	Early online date - 11 Jan 2021

Access to Document

10.2217/fon-2020-1048Licence: CC BY-NC-ND

MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 1.91 MBLicence: CC BY-NC-ND

Cite this

Verstovsek, S., Chen, C.-C., Egyed, M., Ellis, M., Fox, L., Goh, Y. T., Gupta, V., Harrison, C., Kiladjian, J.-J., Lazaroiu, M. C., Mead, A., McLornan, D., McMullin, M. F., Oh, S. T., Perkins, A., Platzbecker, U., Scheid, C., Vannucchi, A., Yoon, S.-S., ... Mesa, R. A. (2021). MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future oncology (London, England). Advance online publication. https://doi.org/10.2217/fon-2020-1048

@article{ef2c3c172bb8455cbb9de7db9710009d,

title = "MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic",

abstract = "Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.",

author = "Srdan Verstovsek and Chih-Cheng Chen and Mikl{\'o}s Egyed and Martin Ellis and Laura Fox and Goh, {Yeow T} and Vikas Gupta and Claire Harrison and Jean-Jacques Kiladjian and Lazaroiu, {Mihaela C} and Adam Mead and Donal McLornan and McMullin, {Mary F} and Oh, {Stephen T} and Andrew Perkins and Uwe Platzbecker and Christof Scheid and Alessandro Vannucchi and Sung-Soo Yoon and Kowalski, {Mark M} and Mesa, {Ruben A}",

year = "2021",

month = jan,

day = "11",

doi = "10.2217/fon-2020-1048",

language = "English",

journal = "Future oncology (London, England)",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

}

Verstovsek, S, Chen, C-C, Egyed, M, Ellis, M, Fox, L, Goh, YT, Gupta, V, Harrison, C, Kiladjian, J-J, Lazaroiu, MC, Mead, A, McLornan, D, McMullin, MF, Oh, ST, Perkins, A, Platzbecker, U, Scheid, C, Vannucchi, A, Yoon, S-S, Kowalski, MM & Mesa, RA 2021, 'MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic', Future oncology (London, England). https://doi.org/10.2217/fon-2020-1048

TY - JOUR

T1 - MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

AU - Verstovsek, Srdan

AU - Chen, Chih-Cheng

AU - Egyed, Miklós

AU - Ellis, Martin

AU - Fox, Laura

AU - Goh, Yeow T

AU - Gupta, Vikas

AU - Harrison, Claire

AU - Kiladjian, Jean-Jacques

AU - Lazaroiu, Mihaela C

AU - Mead, Adam

AU - McLornan, Donal

AU - McMullin, Mary F

AU - Oh, Stephen T

AU - Perkins, Andrew

AU - Platzbecker, Uwe

AU - Scheid, Christof

AU - Vannucchi, Alessandro

AU - Yoon, Sung-Soo

AU - Kowalski, Mark M

AU - Mesa, Ruben A

PY - 2021/1/11

Y1 - 2021/1/11

N2 - Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

AB - Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

U2 - 10.2217/fon-2020-1048

DO - 10.2217/fon-2020-1048

M3 - Article

C2 - 33423550

SN - 1479-6694

JO - Future oncology (London, England)

JF - Future oncology (London, England)

ER -

MOMENTUM momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Abstract

Access to Document

Fingerprint

Cite this